[1] Karatas OF, Oner M, Abay A, et al. MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications [J]. Oral Oncol, 2017, 67:124-130. [2] Hussein AA, Helder MN, de Visscher JG, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review [J]. Eur J Cancer, 2017, 82:115-127. [3] Padhye S, Dandawate P, Yusufi M, et al. Perspectives on medicinal properties of plumbagin and its analogs [J]. Med Res Rev, 2012, 32(6):1131-1158. [4] Yu T, Xu Y, Zhang Y, et al. Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitro [J]. Int Immunopharmacol, 2018, 55:290-296. [5] Chrastina A, Baron VT, Abedinpour P, et al. Plumbagin-loaded nanoemulsion drug delivery formulation and evaluation of antiproliferative effect on prostate cancer cells [J]. Biomed Res Int, 2018, 2018:903545. [6] Kawiak A, Domachowska A, Jaworska A, et al. Plumbagin sensitizes breast cancer cells to tamoxifen-induced cell death through GRP78 inhibition and Bik upregulation [J]. Sci Rep, 2017, 7:43781. [7] Zhou R, Wu K, Su M, et al. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma [J]. Environ Toxicol Pharmacol, 2019, 70:103200. [8] 周雄明,那思家,潘淑婷,等.白花丹素对舌鳞状细胞癌细胞的侵袭和迁移的作用及机制研究[J].口腔医学研究,2018,34(1):39-43. [9] Na S, Zhang J, Zhou X, et al. Plumbagin-mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma [J]. Oral Dis, 2018, 24(6):920-929. [10] Pan ST, Qin Y, Zhou ZW, et al. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells [J]. Drug Des Devel Ther, 2015, 9:1601-1626. [11] Siegel R, Ma J, Zou Z, et al. Cancer statistics,2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29. [12] Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883. [13] Tripathi SK, Panda M, Biswal BK. Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapy [J]. Food Chem Toxicol, 2019, 125:566-582. [14] Perillo B, Di Donato M, Pezone A, et al. ROS in cancer therapy: the bright side of the moon [J]. Exp Mol Med, 2020, 52(2):192-203. [15] Kim SJ, Kim HS, Seo YR. Understanding of ROS-Inducing Strategy in Anticancer Therapy [J]. Oxid Med Cell Longev, 2019, 2019:5381692. [16] Ren X, Boriero D, Chaiswing L, et al. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors [J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1088-1097. [17] Huang H, Xie H, Pan Y, et al. Plumbagin triggers ER stress-mediated apoptosis in prostate cancer cells via induction of ROS [J]. Cell Physiol Biochem, 2018, 45(1):267-280. [18] Shen H, Liu Z. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species [J]. Free Radic Biol Med, 2006, 40(6):928-939. |